Login / Signup

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies.

Ryotaro OhkumaKatsuaki IeguchiMakoto WatanabeDaisuke TakayanagiTsubasa GoshimaRie OnoueKazuyuki HamadaYutaro KubotaAtsushi HoriikeTomoyuki IshiguroYuya HirasawaHirotsugu AriizumiJunji TsurutaniKiyoshi YoshimuraMayumi TsujiYuji KiuchiShinichi KobayashiTakuya TsunodaSatoshi Wada
Published in: Biomedicines (2021)
Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with various cancers. However, many patients are non-responders or develop resistance following an initial response to ICIs. There are no reliable biomarkers to predict the therapeutic effect of ICIs. Therefore, this study investigated the clinical implications of plasma levels of soluble anti-programmed death-1 (sPD-1) in patients with cancer treated with ICIs. In total, 22 patients (13 with non-small-cell lung carcinoma, 8 with gastric cancer, and 1 with bladder cancer) were evaluated for sPD-1 concentration using enzyme-linked immunosorbent assays for diagnostic and anti-PD-1 antibody analyses. sPD-1 levels were low before the administration of anti-PD-1 antibodies. After two and four cycles of anti-PD-1 antibody therapy, sPD-1 levels significantly increased compared with pretreatment levels ( p = 0.0348 vs. 0.0232). We observed an increased rate of change in plasma sPD-1 concentrations after two and four cycles of anti-PD-1 antibody therapy that significantly correlated with tumor size progression ( p = 0.024). sPD-1 may be involved in resistance to anti-PD-1 antibody therapy, suggesting that changes in sPD-1 levels can identify primary ICI non-responders early in treatment. Detailed analysis of each cancer type revealed the potential of sPD-1 as a predictive biomarker of response to ICI treatment in patients with cancer.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • single cell
  • ejection fraction
  • cell therapy
  • peritoneal dialysis
  • bone marrow
  • mesenchymal stem cells
  • climate change
  • high resolution